2 results
Approved WMOCompleted
The aim of this study is to investigate what proportion of HBeAg negative, inactive carriers of the hepatitis B virus with low (< 20,000 IU/mL) load will lose HBsAg when treated with nucleot(s)ide analogue/Peg-IFN combination therapy.
Approved WMORecruiting
The primary aim is to investigate the effect of neuromodulation (via UCon) on the symptoms of patients with PGAD. The hypothesis we want to test is whether neuromodulation of the DGN reduces the severity of symptoms of PGAD.